Plasma neuropeptide Y immunoreactivity influences left ventricular mass in pheochromocytoma

被引:12
作者
Kuch-Wocial, A
Slubowska, K
Kostrubiec, M
Pasierski, T
Januszewicz, W
Switalska, H
Wocial, B
Pruszczyk, P
机构
[1] Med Univ Warsaw, Dept Internal Med & Hypertens, PL-02097 Warsaw, Poland
[2] Cent Hosp, Dept Cardiol, Warsaw, Poland
关键词
pheochromocytoma; NPY; catecholamines; left ventricular hypertrophy;
D O I
10.1016/j.cccn.2004.01.027
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Left ventricular hypertrophy (LVH) in patients with arterial hypertension is closely related to the levels of blood pressurE (BP), catecholamines, angiotensin 11 and other mitogenic peptides. Pheochromocytoma (pheo) is a type of hypertension caused by excessive production of catecholamines. The aim of this study was to determinate if left ventricular hypertrophy in patients with pheochromocytoma is related to catecholamines and neuropeptide Y (NPY). Methods: 29 patients with pheochromocytoma (22 F, age 40 +/- 13 years), plasma concentration of neuropeptide Y immunoreactivity, noradrenaline (NA), and adrenaline (A) were determined. Twenty-four hour urine collection for determination of noradrenaline and adrenaline were performed. Every patient had echocardiographic examination and 24 h ambulatory blood pressure monitoring. Results: Left ventricular hypertrophy was diagnosed in 14 patients. No differences in systolic and diastolic blood pressure in patients with and without left ventricular hypertrophy were found. Plasma noradrenaline and adrenaline levels did not differ between both groups; while plasma neuropeptide Y immunoreactivity was higher in patients with left ventricular hypertrophy than in patients without left ventricular hypertrophy (18.46 +/- 13.26 vs. 9.3 +/- 5.9 fmol/ml (p=0.02)). Left ventricular mass index (LVMI) correlated with plasma neuropeptide Y-immunoreactivity (r=0.42 p=0.023), however, no relationship between left ventricular mass index and plasma or urine noradrenaline and adrenaline levels were found. Conclusion: Our results indicate that mitogenic effect of neuropeptide Y may play a role in pathogenesis of left ventricular hypertrophy in patients with pheochromocytoma. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 16 条
[11]  
NICHOLL SM, 1923, EUR J PHARMACOL, V19, P441
[12]   Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor? [J].
Pruszczyk, P ;
Wocial, B ;
IgnatowskaSwitalska, H ;
Feltynowski, T ;
Ellafi, M ;
Januszewicz, A ;
Lapinski, M ;
ZukowskaGrojec, Z ;
Januszewicz, W .
CLINICA CHIMICA ACTA, 1995, 243 (02) :205-212
[13]   ECHOCARDIOGRAPHIC FINDINGS IN PHEOCHROMOCYTOMA [J].
SHUB, C ;
CUETOGARCIA, L ;
SHEPS, SG ;
ILSTRUP, DM ;
TAJIK, AJ .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (11) :971-975
[14]   PLASMA-CONCENTRATION OF NEUROPEPTIDE-Y IN PATIENTS WITH ADRENAL HYPERTENSION [J].
TABARIN, A ;
MINOT, AP ;
DALLOCHIO, M ;
ROGER, P ;
DUCASSOU, D .
REGULATORY PEPTIDES, 1992, 42 (1-2) :51-61
[15]   The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte [J].
Zeng, C ;
Zhou, Y ;
Liu, G ;
Sun, W .
NEUROPEPTIDES, 2001, 35 (5-6) :211-218
[16]   MITOGENIC EFFECT OF NEUROPEPTIDE-Y IN RAT VASCULAR SMOOTH-MUSCLE CELLS [J].
ZUKOWSKAGROJEC, Z ;
PRUSZCZYK, P ;
COLTON, C ;
YAO, JB ;
SHEN, GH ;
MYERS, AK ;
WAHLESTEDT, C .
PEPTIDES, 1993, 14 (02) :263-268